Comparing SG&A Expenses: Biogen Inc. vs Dr. Reddy's Laboratories Limited Trends and Insights

Biogen vs. Dr. Reddy's: SG&A Expense Trends Unveiled

__timestampBiogen Inc.Dr. Reddy's Laboratories Limited
Wednesday, January 1, 2014223234200038783000000
Thursday, January 1, 2015211310000042585000000
Friday, January 1, 2016194790000045702000000
Sunday, January 1, 2017193550000046372000000
Monday, January 1, 2018210630000046910000000
Tuesday, January 1, 2019237470000048890000000
Wednesday, January 1, 2020250450000050129000000
Friday, January 1, 2021267430000054559000000
Saturday, January 1, 2022240360000062081000000
Sunday, January 1, 20232549700000105931000000
Monday, January 1, 2024240370000077201000000
Loading chart...

Infusing magic into the data realm

SG&A Expenses: A Tale of Two Pharmaceutical Giants

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Biogen Inc. and Dr. Reddy's Laboratories Limited from 2014 to 2023. Over this period, Dr. Reddy's Laboratories consistently outpaced Biogen, with SG&A expenses peaking at over $105 billion in 2023, a staggering 300% increase from 2014. In contrast, Biogen's expenses showed a more modest growth, peaking at approximately $2.67 billion in 2021, reflecting a 20% increase from 2014. This disparity highlights the differing strategic priorities and market challenges faced by these companies. Notably, the data for 2024 is incomplete, indicating potential shifts in future trends. As the pharmaceutical landscape continues to change, these insights provide a window into the operational strategies of these industry leaders.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025